Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis.

Pan C, Issaeva N, Yarbrough WG.

Cancers Head Neck. 2018 Dec 29;3:12. doi: 10.1186/s41199-018-0039-3. eCollection 2018. Review.

2.

p53 Signaling in Cancers.

Issaeva N.

Cancers (Basel). 2019 Mar 8;11(3). pii: E332. doi: 10.3390/cancers11030332.

3.

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B.

Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.

4.

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.

Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP.

Oncogene. 2019 May;38(18):3475-3487. doi: 10.1038/s41388-018-0657-6. Epub 2019 Jan 15.

PMID:
30647454
5.

Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers.

Cheng H, Yang X, Si H, Saleh AD, Xiao W, Coupar J, Gollin SM, Ferris RL, Issaeva N, Yarbrough WG, Prince ME, Carey TE, Van Waes C, Chen Z.

Cell Rep. 2018 Oct 30;25(5):1332-1345.e5. doi: 10.1016/j.celrep.2018.10.007.

6.

Advances in biomarkers and treatment strategies for HPV-associated head and neck cancer.

Pan C, Yarbrough WG, Issaeva N.

Oncoscience. 2018 Jun 25;5(5-6):140-141. doi: 10.18632/oncoscience.425. eCollection 2018 May. No abstract available.

7.

Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2018 Aug 15;78(16):4613-4626. doi: 10.1158/0008-5472.CAN-17-0642. Epub 2018 Jun 19.

PMID:
29921694
8.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2017 Dec 1;292(48):19607. doi: 10.1074/jbc.AAC117.000815. No abstract available.

9.

Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.

Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N.

Clin Cancer Res. 2017 Dec 1;23(23):7276-7287. doi: 10.1158/1078-0432.CCR-17-1438. Epub 2017 Sep 15.

10.

Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner.

Wamsley JJ, Gary C, Biktasova A, Hajek M, Bellinger G, Virk R, Issaeva N, Yarbrough WG.

Oncogenesis. 2017 Apr 10;6(4):e314. doi: 10.1038/oncsis.2017.12.

11.

TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N.

Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.

12.

LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.

Wamsley JJ, Issaeva N, An H, Lu X, Donehower LA, Yarbrough WG.

Cell Cycle. 2017 Jan 17;16(2):213-223. doi: 10.1080/15384101.2016.1261767. Epub 2016 Dec 27.

13.

Selective antitumor activity of roscovitine in head and neck cancer.

Gary C, Hajek M, Biktasova A, Bellinger G, Yarbrough WG, Issaeva N.

Oncotarget. 2016 Jun 21;7(25):38598-38611. doi: 10.18632/oncotarget.9560.

14.

ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.

Fleyshman D, Cheney P, Ströse A, Mudambi S, Safina A, Commane M, Purmal A, Morgan K, Wang NJ, Gray J, Spellman PT, Issaeva N, Gurova K.

Cell Cycle. 2016;15(3):455-70. doi: 10.1080/15384101.2015.1127478. Epub 2015 Dec 22.

15.

In vitro model for gastroduodenal reflux-induced nuclear factor-kappaB activation and its role in hypopharyngeal carcinogenesis.

Sasaki CT, Issaeva N, Vageli DP.

Head Neck. 2016 Apr;38 Suppl 1:E1381-91. doi: 10.1002/hed.24231. Epub 2015 Nov 11.

PMID:
26559497
16.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

17.

Characterization of HPV and host genome interactions in primary head and neck cancers.

Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R; Cancer Genome Atlas Network.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9. doi: 10.1073/pnas.1416074111. Epub 2014 Oct 13.

18.

Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.

Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG.

Clin Cancer Res. 2014 May 1;20(9):2300-11. doi: 10.1158/1078-0432.CCR-13-2585. Epub 2014 Mar 5.

19.

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.

Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, Eriksson S, Hedström E, Issaeva N, Kel A, Arnér ES, Selivanova G.

Cell Death Differ. 2014 Apr;21(4):612-23. doi: 10.1038/cdd.2013.186. Epub 2014 Jan 10.

20.

SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways.

Gubanova E, Issaeva N, Gokturk C, Djureinovic T, Helleday T.

Cell Cycle. 2013 Dec 15;12(24):3770-80. doi: 10.4161/cc.26660. Epub 2013 Oct 4.

21.

TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.

Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK, Yarbrough WG.

Oncogene. 2013 Aug 8;32(32):3698-710. doi: 10.1038/onc.2012.377. Epub 2012 Oct 1.

PMID:
23027130
22.

Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis.

Uzhachenko R, Issaeva N, Boyd K, Ivanov SV, Carbone DP, Ivanova AV.

J Pathol. 2012 Aug;227(4):456-69. doi: 10.1002/path.4039. Epub 2012 Jun 6.

PMID:
22513871
23.

Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival.

Gubanova E, Brown B, Ivanov SV, Helleday T, Mills GB, Yarbrough WG, Issaeva N.

Clin Cancer Res. 2012 Mar 1;18(5):1257-67. doi: 10.1158/1078-0432.CCR-11-2058. Epub 2012 Jan 13.

24.

Tumor suppressor Lzap regulates cell cycle progression, doming, and zebrafish epiboly.

Liu D, Wang WD, Melville DB, Cha YI, Yin Z, Issaeva N, Knapik EW, Yarbrough WG.

Dev Dyn. 2011 Jun;240(6):1613-25. doi: 10.1002/dvdy.22644. Epub 2011 Apr 26.

25.

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.

Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Strömblad S.

Cell Cycle. 2011 Jan 15;10(2):301-7. Epub 2011 Jan 15.

PMID:
21239882
26.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T.

Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734. Djurenovic, Tatjana [corrected to Djureinovic, Tatjana].

27.

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T.

Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15. Erratum in: Cancer Res. 2011 Apr 1;71(7):2803.

28.

Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T.

Mol Cell. 2010 Feb 26;37(4):492-502. doi: 10.1016/j.molcel.2010.01.021.

29.

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.

Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T.

EMBO J. 2009 Sep 2;28(17):2601-15. doi: 10.1038/emboj.2009.206. Epub 2009 Jul 23.

30.

Tumor-specific induction of apoptosis by a p53-reactivating compound.

Hedström E, Issaeva N, Enge M, Selivanova G.

Exp Cell Res. 2009 Feb 1;315(3):451-61. doi: 10.1016/j.yexcr.2008.11.009. Epub 2008 Dec 3.

PMID:
19071110
31.

RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells.

Sleeth KM, Sørensen CS, Issaeva N, Dziegielewski J, Bartek J, Helleday T.

J Mol Biol. 2007 Oct 12;373(1):38-47. Epub 2007 Aug 15.

PMID:
17765923
32.

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG.

Nature. 2006 Nov 30;444(7119):633-7.

PMID:
17136093
33.

Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner.

Zawacka-Pankau J, Issaeva N, Hossain S, Pramanik A, Selivanova G, Podhajska AJ.

J Biol Chem. 2007 Jan 26;282(4):2466-72. Epub 2006 Nov 29.

34.

Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy.

Zawacka-Pankau J, Kowalska A, Issaeva N, Burcza A, Kwiek P, Bednarz N, Pramanik A, Banecki B, Podhajska AJ.

J Photochem Photobiol B. 2007 Jan 3;86(1):35-42. Epub 2006 Sep 20.

PMID:
16990010
35.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2005 Aug 26;280(34):30384-91. Epub 2005 Jul 1. Erratum in: J Biol Chem. 2017 Dec 1;292(48):19607.

36.

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G.

Nat Med. 2004 Dec;10(12):1321-8. Epub 2004 Nov 21.

PMID:
15558054
37.

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7. Epub 2003 Oct 31.

39.

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G.

Nat Med. 2002 Mar;8(3):282-8.

PMID:
11875500
40.

Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Heessen S, Leonchiks A, Issaeva N, Sharipo A, Selivanova G, Masucci MG, Dantuma NP.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1532-7. Epub 2002 Jan 22.

Supplemental Content

Loading ...
Support Center